Innovative Neurovascular Technology Sequent Medical has developed the proprietary Microbraid technology and the WEB® Aneurysm Embolization System, which demonstrates a focus on minimally invasive neurovascular solutions. This positions the company as a key player for healthcare providers seeking advanced aneurysm treatment options.

Expansion and Market Reach The WEB device has gained CE mark approval and has been adopted in Europe and Latin America, indicating strong international presence and compliance with regulatory standards—potentially open to US market entry pending regulatory approval.

Recent Acquisition Advantage Since being acquired by Terumo in 2016 for $380 million, Sequent Medical benefits from increased resources and global distribution channels, presenting sales opportunities through expanded access and branding.

Growing Revenue Potential With current revenues estimated between $1 million and $10 million and $20 million in funding, there is significant growth potential, especially as the company expands product adoption and enters new markets.

Complementary Industry Presence Sequent operates within a competitive landscape alongside larger neurovascular device firms like Penumbra and Stryker, suggesting opportunities for strategic partnerships, collaborations, or tailored solutions to differentiate and accelerate sales in this niche.